+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "In Situ Hybridization"

Oncology Molecular Diagnostics Global Market Report 2024 - Product Thumbnail Image

Oncology Molecular Diagnostics Global Market Report 2024

  • Report
  • February 2024
  • 250 Pages
  • Global
From
From
Point-Of-Care Molecular Diagnostics Global Market Report 2024 - Product Thumbnail Image

Point-Of-Care Molecular Diagnostics Global Market Report 2024

  • Report
  • December 2023
  • 200 Pages
  • Global
From
From
From
From
From
From
From
From
Loading Indicator

In Situ Hybridization (ISH) is a molecular diagnostic technique used to detect and localize specific nucleic acid sequences within cells and tissues. It is used to detect gene expression, chromosomal abnormalities, and gene mutations. ISH is a powerful tool for diagnosing diseases such as cancer, genetic disorders, and infectious diseases. ISH involves the use of labeled probes, which are complementary to the target nucleic acid sequence. The probes are hybridized to the target sequence, and the labeled probes are detected using a variety of techniques, such as fluorescence microscopy, immunohistochemistry, and in situ PCR. ISH is used in a variety of clinical applications, including the diagnosis of cancer, genetic disorders, and infectious diseases. It is also used in research to study gene expression, chromosomal abnormalities, and gene mutations. Companies in the In Situ Hybridization market include Agilent Technologies, Bio-Rad Laboratories, Merck KGaA, PerkinElmer, and Thermo Fisher Scientific. Show Less Read more